Infectious Diseases and Clinical Microbiology Department, Ankara Numune Education and Research Hospital, 06100 Samanpazarı, Ankara, Turkey.
Int J Infect Dis. 2011 Jan;15(1):e44-7. doi: 10.1016/j.ijid.2010.09.009. Epub 2010 Nov 23.
Crimean-Congo hemorrhagic fever (CCHF) is a lethal hemorrhagic disease. There is currently no specific antiviral therapy for CCHF approved for use in humans. In this study we aimed to investigate the effect of oral ribavirin treatment on the viral load and disease progression in CCHF.
The study population was composed of patients who had a definitive diagnosis of CCHF by means of clinical presentation plus detection of viral RNA by reverse transcriptase polymerase chain reaction (RT-PCR). Ten patients who received oral ribavirin for 10 days and 40 control patients who received supportive treatment only were included in the study. Ribavirin treatment consisted of oral ribavirin 4 g/day for 4 days and then 2.4 g/day for 6 days. Viral load and hematological and biochemical laboratory parameters, which were measured daily, were analyzed.
Mean age (37.4 vs. 45.5, p=0.285), gender (male 50% vs. 62.5%, p=0.470), days from the appearance of symptoms to admission (4.3 vs.4.4 days, p=0.922), and initial complaints were similar between the ribavirin group and the control group. Upon hospital admission, mean viral load was 8.2×10⁸ copies/ml in the ribavirin group and 8.3×10⁸ copies/ml in the control group (p=0.994). During follow-up, no statistically significant differences were found between the groups with regard to the decrease in viral load, the reduction in alanine aminotransferase and aspartate aminotransferase levels, and the increase in platelet count. The case-fatality rate was 20% (2/10 patients) in the ribavirin group and 15% (6/40 patients) in the control group (p=0.509).
In this study, oral ribavirin treatment in CCHF patients did not affect viral load or disease progression.
克里米亚-刚果出血热（CCHF）是一种致命的出血性疾病。目前尚无经批准可用于人类的针对 CCHF 的特定抗病毒疗法。在这项研究中，我们旨在研究口服利巴韦林治疗对 CCHF 病毒载量和疾病进展的影响。
研究人群由通过临床症状加上逆转录聚合酶链反应（RT-PCR）检测到病毒 RNA 而明确诊断为 CCHF 的患者组成。10 名接受 10 天口服利巴韦林治疗的患者和 40 名仅接受支持性治疗的对照患者被纳入研究。利巴韦林治疗包括 4 天每天 4g，然后 6 天每天 2.4g。每天测量病毒载量和血液学及生化实验室参数，并进行分析。
平均年龄（37.4 岁比 45.5 岁，p=0.285）、性别（男性 50%比 62.5%，p=0.470）、从出现症状到入院的天数（4.3 天比 4.4 天，p=0.922）和初始症状在利巴韦林组和对照组之间相似。入院时，利巴韦林组的平均病毒载量为 8.2×10⁸拷贝/ml，对照组为 8.3×10⁸拷贝/ml（p=0.994）。在随访期间，两组之间在病毒载量下降、丙氨酸氨基转移酶和天冬氨酸氨基转移酶水平降低以及血小板计数增加方面均无统计学差异。利巴韦林组的病死率为 20%（2/10 例患者），对照组为 15%（6/40 例患者）（p=0.509）。
在这项研究中，CCHF 患者口服利巴韦林治疗并未影响病毒载量或疾病进展。
Zotero 插件